Hello, Fool! | Login | Signup | My Fool
May 17, 2008 1:28 AM ET | Site Changes | Help
Search: Tickers Company Names Players
The Company designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite, or cath lab.
View All Commentary (STXS)
Recs
joel415 (89.80) Submitted: 8/03/07 10:40 AM : Start Price: $12.00 STXS Score: -49.51
It looks like the days of doctors manually trying to push tubes around the body in the cath lab are almost over. Both STXS and HNSN make systems that are essentially disruptive technologies. They enable cariologist to deal with tougher cases, quicker, with fewer years of training and without exposing themselves to nearly as much radiation as the traditional "by hand" methods call for. I like STXS better because it's got more equipment in the field already and broader indications than HNSN. But there are far more folks at the Fool who love HNSN because of its connection to the founder of ISRG. I think all the posturing is ridiculous. We're watching the beginnings of a duopoly which is going to turn a lot of stuff upside down when it comes to non-invasive surgery. STXS may have an early lead. HNSN may catch up. Who cares? Both companies -- if managed well -- should do well. That said, of course, I think STXS will do better... but that's just my $.02.
Report this Post Replies: 1 | Reply
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
joel415 (89.80) Submitted: 3/17/08 7:13 PM
Recs: 0 | Rec This
Wow, like any other long-term holders, I just got my butt kicked. But if you own shares, or are thinking about buying, consider sticking with it. The stock is cheap (by price/sales, price/book), it's likely to keep growing fast, and insiders are buying oodles of stock.
Report this Post Reply